Floatz logo

Octreotide Pamoate

Pancreatic Neuroendocrine Tumor G1

National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Pancreatic Neuroendocrine Tumor G1 cohort.

Asset / SponsorPhaseRating
Oxodotreotide
Vanderbilt-Ingram Cancer Center
Phase 4BB
Everolimus
AC Camargo Cancer Center
Phase 2B
Tak-228
National Cancer Institute (NCI)
Phase 2B
[212pb] vmt-α-net
David Bushnell
Early Phase 1C

Same molecule, other indications

Octreotide Pamoate is also rated in:

diarrheal diseaseDormant
BB
Indicative ·
71 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
71 / 100
View asset →
esophageal varicesDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →